ALK and non-small cell lung carcinoma: ExoDx Lung (ALK) has a sensitivity of 88% and a specificity of 100% in detecting NSCLC and is useful for doctors to determine therapeutic regimen, especially for those patients who are unable or unwilling to accept tissue biopsy (Zhang et al., 2020).